Axovant Gene Therapies Stock Price, News & Analysis (NASDAQ:AXGT)

+0.24 (+3.19 %)
(As of 09/22/2019 04:00 PM ET)
Today's Range
Now: $7.77
50-Day Range
MA: $6.92
52-Week Range
Now: $7.77
Volume116,440 shs
Average Volume95,922 shs
Market Capitalization$177.00 million
P/E RatioN/A
Dividend YieldN/A
Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing a pipeline of product candidates for debilitating neurological and neuromuscular diseases. The company's current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis, Parkinson's disease, oculopharyngeal muscular dystrophy, amyotrophic lateral sclerosis, and frontotemporal dementia. The company was formerly known as Axovant Sciences Ltd. The company was founded in 2014 and is based in New York, New York. Axovant Gene Therapies Ltd. operates as a subsidiary of Roivant Sciences Ltd.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:AXGT



Sales & Book Value

Annual SalesN/A
Book Value$2.47 per share


Net Income$-129,070,000.00


Market Cap$177.00 million
Next Earnings Date11/6/2019 (Estimated)

Receive AXGT News and Ratings via Email

Sign-up to receive the latest news and ratings for AXGT and its competitors with MarketBeat's FREE daily newsletter.

Axovant Gene Therapies (NASDAQ:AXGT) Frequently Asked Questions

What is Axovant Gene Therapies' stock symbol?

Axovant Gene Therapies trades on the NASDAQ under the ticker symbol "AXGT."

When did Axovant Gene Therapies' stock split? How did Axovant Gene Therapies' stock split work?

Shares of Axovant Gene Therapies reverse split on the morning of Wednesday, May 8th 2019. The 1-8 reverse split was announced on Tuesday, May 7th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 7th 2019. An investor that had 100 shares of Axovant Gene Therapies stock prior to the reverse split would have 13 shares after the split.

How were Axovant Gene Therapies' earnings last quarter?

Axovant Gene Therapies Ltd (NASDAQ:AXGT) released its quarterly earnings results on Friday, August, 9th. The company reported ($1.23) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.34) by $0.11. View Axovant Gene Therapies' Earnings History.

When is Axovant Gene Therapies' next earnings date?

Axovant Gene Therapies is scheduled to release their next quarterly earnings announcement on Wednesday, November 6th 2019. View Earnings Estimates for Axovant Gene Therapies.

What price target have analysts set for AXGT?

9 brokers have issued 12-month price objectives for Axovant Gene Therapies' stock. Their predictions range from $5.79 to $56.00. On average, they expect Axovant Gene Therapies' stock price to reach $29.8271 in the next year. This suggests a possible upside of 283.9% from the stock's current price. View Analyst Price Targets for Axovant Gene Therapies.

What is the consensus analysts' recommendation for Axovant Gene Therapies?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axovant Gene Therapies in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Axovant Gene Therapies.

What are Wall Street analysts saying about Axovant Gene Therapies stock?

Here are some recent quotes from research analysts about Axovant Gene Therapies stock:
  • 1. According to Zacks Investment Research, "Axovant Sciences Ltd. is a biopharmaceutical company which focuses on the acquisition, development and commercialization of therapeutics for the treatment of neurodegenerative disorders. Its product candidate includes RVT-101 which is in different clinical trial for the treatment of Alzheimer's disease and other forms of dementia. Axovant Sciences Ltd. is based in Hamilton, Bermuda. " (8/14/2019)
  • 2. Cowen Inc analysts commented, ". We reiterate our Overweight rating and $221 Price Target. Amgen posted an strong top-line at $5.56B vs Bloomberg consensus of $5.51B and a bottom-line beat with EPS of $3.56 vs consensus of $3.49. This also included the ASR of $3B in 1Q 2019. Key update was raising of the low end of revenue and EPS guidance, so range is now $22.0-22.9B and $13.25-14.30/sh from $21.8-22.9B and $13.10-$14.30/sh previously based on 1Q results. Though the company noted this reflects a range of outcomes for Sensipar, this adjustment suggests it had been accounting for the potential for additional top-line pressure in 1Q." (5/1/2019)
  • 3. HC Wainwright analysts commented, "Our price target of $7/share is based on an equally-weighted composite of: (a) $5.56/share, as a 35x multiple of taxed and diluted $1.70 discounted back to FY19 at 20% (in line with the expected PE multiple and discount rate of an early development-stage biotechnology company); and (b) an NPV of $9.23/ share (discounted cash flow analysis using a 15% discount rate and 2.0% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company)." (3/12/2019)
  • 4. Chardan Capital analysts commented, "We upgrade Buy (low conviction), maintaining our price target at $4/share. This morning, Axovant announced updates from 2 of its clinical programs, showing: (1) encouraging interim results at 3 months from Cohort 1 (lower dose of 4.2×10^6 the phase II SUNRISE-PD trial (NCT03720418) of AXO-Lenti-PD gene therapy (GT) in Parkinson’s disease (PD), and (2) 3- month data showing enzyme activity in an investigator-initiated study (dose of 1.0x 10^14 vg) of AXO-AAV-GM2 GT in Tay-Sachs disease." (3/11/2019)

Has Axovant Gene Therapies been receiving favorable news coverage?

Media coverage about AXGT stock has trended somewhat negative recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Axovant Gene Therapies earned a media sentiment score of -1.3 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Axovant Gene Therapies.

Are investors shorting Axovant Gene Therapies?

Axovant Gene Therapies saw a increase in short interest in the month of August. As of August 31st, there was short interest totalling 1,225,900 shares, an increase of 15.5% from the July 31st total of 1,061,600 shares. Based on an average daily trading volume, of 643,100 shares, the days-to-cover ratio is presently 1.9 days. Approximately 5.4% of the company's shares are sold short. View Axovant Gene Therapies' Current Options Chain.

Who are some of Axovant Gene Therapies' key competitors?

What other stocks do shareholders of Axovant Gene Therapies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axovant Gene Therapies investors own include The Medicines (MDCO), New Age Beverages (NBEV), Amarin (AMRN), Conatus Pharmaceuticals (CNAT), Illumina (ILMN), Nabriva Therapeutics (NBRV), Viking Therapeutics (VKTX), Zynerba Pharmaceuticals (ZYNE), Aphria (APHA) and ADMA Biologics (ADMA).

Who are Axovant Gene Therapies' key executives?

Axovant Gene Therapies' management team includes the folowing people:
  • Dr. Pavan Cheruvu M.D., CEO & Director (Age 37)
  • Dr. Gregory M. Weinhoff, Principal Financial & Accounting Officer (Age 48)
  • Dr. David T. Hung M.D., Scientific Advisor of Group (Age 61)
  • Dr. Fraser Wright, Chief Technology Officer
  • Ms. Tricia Truehart, Head of Investor Relations

Who are Axovant Gene Therapies' major shareholders?

Axovant Gene Therapies' stock is owned by a number of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (1.45%), BlackRock Inc. (1.04%), Primecap Management Co. CA (0.55%), Jane Street Group LLC (0.20%), GSA Capital Partners LLP (0.11%) and Royal Bank of Canada (0.06%). Company insiders that own Axovant Gene Therapies stock include Atul Pande, Pavan Cheruvu and Svf Investments (Uk) Ltd. View Institutional Ownership Trends for Axovant Gene Therapies.

Which major investors are selling Axovant Gene Therapies stock?

AXGT stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Primecap Management Co. CA, GSA Capital Partners LLP and Royal Bank of Canada. View Insider Buying and Selling for Axovant Gene Therapies.

Which major investors are buying Axovant Gene Therapies stock?

AXGT stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Jane Street Group LLC and Tower Research Capital LLC TRC . Company insiders that have bought Axovant Gene Therapies stock in the last two years include Atul Pande, Pavan Cheruvu and Svf Investments (Uk) Ltd. View Insider Buying and Selling for Axovant Gene Therapies.

How do I buy shares of Axovant Gene Therapies?

Shares of AXGT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Axovant Gene Therapies' stock price today?

One share of AXGT stock can currently be purchased for approximately $7.77.

How big of a company is Axovant Gene Therapies?

Axovant Gene Therapies has a market capitalization of $177.00 million. The company earns $-129,070,000.00 in net income (profit) each year or ($8.02) on an earnings per share basis. Axovant Gene Therapies employs 45 workers across the globe.View Additional Information About Axovant Gene Therapies.

What is Axovant Gene Therapies' official website?

The official website for Axovant Gene Therapies is

How can I contact Axovant Gene Therapies?

Axovant Gene Therapies' mailing address is 11-12 ST. JAMES`S SQUARE SUITE 1 3RD FLOOR, LONDON X0, 10036. The company can be reached via phone at 833-296-8268.

MarketBeat Community Rating for Axovant Gene Therapies (NASDAQ AXGT)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  30 (Vote Outperform)
Underperform Votes:  28 (Vote Underperform)
Total Votes:  58
MarketBeat's community ratings are surveys of what our community members think about Axovant Gene Therapies and other stocks. Vote "Outperform" if you believe AXGT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXGT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/22/2019 by Staff

Featured Article: What is a support level?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel